Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

NCT03371108 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

567

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL: Gan & Lee Insulin Glargine Injection
BIOLOGICAL: Lantus®

Sponsor

Gan and Lee Pharmaceuticals, USA